Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.
González-Calle V, Rodríguez-Otero P, Sureda A, De Arriba F, Reinoso M, Ribas P, González-Rodríguez AP, González Y, Oriol A, Martínez-López J, González MS, Hernández MT, Sirvent M, Cedena T, Puig N, Paiva B, Bladé J, Lahuerta JJ, San-Miguel JF, Mateos MV.
González-Calle V, et al. Among authors: gonzalez ms.
Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284089. Online ahead of print.
Haematologica. 2024.
PMID: 38356463
Free article.